CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers, forms the TCR-CD3 complex. This complex is crucial for coupling antigen ...

Introduction: Antigen binding to the T cell antigen receptor (TCR) leads to the phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 complex, and thereby to T cell ...

Figure 3 TCRs vs CAR and genetically modified T cells in immunotherapy. Cancer targeting receptors, TCR and CAR, are introduced to the activated T cells to empower them against special type of cancer.

S3). Immunohistochemical analysis showed a dense lymphocytic infiltration of the lamina propria positive for T-cell receptor (TCR) α, CD3, CD4, and granzyme B but which did not express TRBC1 ...

Marcello Lotti has reiterated the stance of WSC Group regarding TCR cars competing in ‘unlicensed events’ by confirming that an entry into such an event will result in a car losing its official ...

今年1月，艾伯维斥资超10亿美元引进先声再明自主研发的靶向GPRC5D/BCMA/CD3三特异性T细胞接合器（TCE）SIM0500 ...

肿瘤治疗始终面临着诸多挑战，提高治疗的特异性、疗效并降低副作用是关键目标。免疫疗法作为一种新兴的治疗手段，在过去几十年中得到了广泛研究。嵌合抗原受体 T（CAR-T）细胞疗法在血液系统恶性肿瘤治疗中取得了显著成效，但存在生产成本高昂、制备过程复杂以及潜在慢性毒副作用等问题。

The DALI tool facilitates linking TCR clonotype information to functional properties ... BioLegend), anti-CD4 (BUV395, BD Biosciences) and anti-CD3 (BUV737, BD Biosciences), anti-Ki-67 (BV786, BD ...

ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic ...

2024年，两款TCE药物全球首次获得批准上市。安进开发的DLL3/CD3 TCE在5月获美国FDA加速批准，用于一线治疗广泛期小细胞肺癌成人患者，为首款用于治疗实体瘤的双特异性TCE。再生元开发的CD20/CD3靶向TCE Odronextamab于8月份获EMA批准上市，首次获批准用于治疗复发或难治性（R/R）滤泡性淋巴瘤或R/R弥漫性大B细胞淋巴瘤成年患者。